Letosteine

Last updated
Letosteine
Letosteine.svg
Clinical data
Trade names Viscotiol
Other names2-[2-(ethoxycarbonylmethylsulfanyl)ethyl]-1,3-thiazolidine-4-carboxylic acid
Routes of
administration
Oral (gastroresistant capsules)
ATC code
Identifiers
  • 2-[2-(2-ethoxy-2-oxoethyl)sulfanylethyl]-1,3-thiazolidine-4-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard 100.053.509 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C10H17NO4S2
Molar mass 279.37 g·mol−1
3D model (JSmol)
  • O=C(O)C1NC(SC1)CCSCC(=O)OCC
  • InChI=1S/C10H17NO4S2/c1-2-15-9(12)6-16-4-3-8-11-7(5-17-8)10(13)14/h7-8,11H,2-6H2,1H3,(H,13,14) Yes check.svgY
  • Key:IKOCLISPVJZJEA-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Letosteine is a mucolytic [1] patented (U.S. patent 6987120) by Piero del Soldato of Milan, Italy. [2] He filed his application in 2000.

References

  1. Zhou Y, Sun S, Liu H, Cui L, Chang X, Sun Z (November 2014). "Efficacy and safety of letosteine in the treatment of sputum thickening and expectoration difficulty in patients with respiratory diseases: a multicenter, randomized, double-masked, double dummy, positive drug parallel controlled trial". Die Pharmazie. 69 (11): 842–9. PMID   25985582.
  2. US 6987120,del Soldato P,"Pharmaceutical compounds",issued 17 January 2006, assigned to Nicox SA